Vistagen (Nasdaq: VTGN) released preliminary data from the open-label extension (OLE) portion of its PALISADE-4 Phase 3 study of fasedienol ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE